| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 108 | 2025 | 498 | 14.950 |
Why?
|
| Influenza, Human | 118 | 2025 | 700 | 14.540 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 45 | 2025 | 189 | 7.030 |
Why?
|
| Vaccination | 92 | 2025 | 1019 | 5.530 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 50 | 2025 | 123 | 4.290 |
Why?
|
| Hospitalization | 61 | 2025 | 1919 | 3.260 |
Why?
|
| Seasons | 53 | 2025 | 333 | 3.260 |
Why?
|
| Health Personnel | 14 | 2025 | 542 | 2.540 |
Why?
|
| Influenza B virus | 31 | 2025 | 100 | 2.480 |
Why?
|
| United States | 110 | 2025 | 11798 | 1.890 |
Why?
|
| Vaccines, Inactivated | 24 | 2025 | 148 | 1.870 |
Why?
|
| Antibodies, Viral | 19 | 2025 | 1205 | 1.760 |
Why?
|
| Adult | 133 | 2025 | 31963 | 1.620 |
Why?
|
| Emergency Responders | 5 | 2022 | 18 | 1.450 |
Why?
|
| Outpatients | 18 | 2025 | 277 | 1.400 |
Why?
|
| Respiratory Tract Infections | 10 | 2023 | 295 | 1.270 |
Why?
|
| Adolescent | 92 | 2025 | 20648 | 1.270 |
Why?
|
| Influenza A virus | 14 | 2025 | 152 | 1.240 |
Why?
|
| Humans | 210 | 2025 | 134223 | 1.180 |
Why?
|
| Young Adult | 63 | 2025 | 9964 | 1.130 |
Why?
|
| Population Surveillance | 15 | 2025 | 419 | 1.100 |
Why?
|
| Middle Aged | 90 | 2025 | 29431 | 1.080 |
Why?
|
| Aged | 82 | 2025 | 21822 | 1.050 |
Why?
|
| Vaccines, Synthetic | 17 | 2025 | 322 | 0.990 |
Why?
|
| Vaccines, Combined | 12 | 2024 | 39 | 0.990 |
Why?
|
| Case-Control Studies | 29 | 2025 | 3678 | 0.950 |
Why?
|
| Viral Load | 4 | 2023 | 411 | 0.940 |
Why?
|
| Child, Preschool | 62 | 2025 | 14898 | 0.850 |
Why?
|
| Prospective Studies | 27 | 2025 | 6617 | 0.850 |
Why?
|
| Respiratory Syncytial Virus Infections | 5 | 2025 | 377 | 0.840 |
Why?
|
| Male | 103 | 2025 | 66216 | 0.820 |
Why?
|
| Vaccine Potency | 6 | 2020 | 9 | 0.820 |
Why?
|
| Female | 106 | 2025 | 72055 | 0.800 |
Why?
|
| Smallpox Vaccine | 1 | 2023 | 38 | 0.790 |
Why?
|
| Ambulatory Care | 11 | 2024 | 416 | 0.760 |
Why?
|
| Hemagglutination Inhibition Tests | 7 | 2025 | 114 | 0.750 |
Why?
|
| Antibody Formation | 5 | 2024 | 274 | 0.710 |
Why?
|
| Spike Glycoprotein, Coronavirus | 6 | 2025 | 204 | 0.710 |
Why?
|
| Occupations | 1 | 2021 | 22 | 0.710 |
Why?
|
| Child | 69 | 2025 | 25918 | 0.710 |
Why?
|
| Occupational Diseases | 1 | 2021 | 75 | 0.670 |
Why?
|
| Infant | 46 | 2025 | 13263 | 0.620 |
Why?
|
| Pneumonia | 1 | 2022 | 343 | 0.590 |
Why?
|
| Immunocompromised Host | 5 | 2024 | 306 | 0.580 |
Why?
|
| RNA, Messenger | 18 | 2024 | 2915 | 0.560 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2025 | 114 | 0.560 |
Why?
|
| Vaccines, Attenuated | 12 | 2018 | 176 | 0.540 |
Why?
|
| Aged, 80 and over | 27 | 2025 | 7244 | 0.520 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 108 | 0.490 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 3 | 2025 | 62 | 0.480 |
Why?
|
| Dementia | 1 | 2020 | 489 | 0.470 |
Why?
|
| Immunization, Secondary | 5 | 2022 | 113 | 0.470 |
Why?
|
| Social Class | 2 | 2013 | 210 | 0.470 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2025 | 71 | 0.450 |
Why?
|
| Emergency Service, Hospital | 12 | 2024 | 1166 | 0.440 |
Why?
|
| Antiviral Agents | 5 | 2025 | 825 | 0.440 |
Why?
|
| Pandemics | 5 | 2023 | 1193 | 0.400 |
Why?
|
| Cell Culture Techniques | 3 | 2024 | 295 | 0.400 |
Why?
|
| Cohort Studies | 12 | 2025 | 5225 | 0.390 |
Why?
|
| Hospital Mortality | 8 | 2025 | 1100 | 0.390 |
Why?
|
| Asthma | 3 | 2008 | 812 | 0.380 |
Why?
|
| Disease Outbreaks | 4 | 2014 | 330 | 0.360 |
Why?
|
| Orthomyxoviridae | 4 | 2014 | 52 | 0.350 |
Why?
|
| Fever | 1 | 2013 | 312 | 0.340 |
Why?
|
| Sentinel Surveillance | 4 | 2025 | 24 | 0.340 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 233 | 0.340 |
Why?
|
| Asymptomatic Infections | 3 | 2025 | 38 | 0.340 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 722 | 0.340 |
Why?
|
| Immunity, Humoral | 3 | 2025 | 75 | 0.330 |
Why?
|
| Health Status Disparities | 1 | 2013 | 252 | 0.330 |
Why?
|
| Critical Illness | 2 | 2023 | 629 | 0.290 |
Why?
|
| Patient Acuity | 3 | 2025 | 67 | 0.290 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 681 | 0.280 |
Why?
|
| Retropharyngeal Abscess | 2 | 1996 | 8 | 0.250 |
Why?
|
| Administration, Intranasal | 7 | 2010 | 138 | 0.240 |
Why?
|
| Oseltamivir | 1 | 2025 | 19 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2025 | 543 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 547 | 0.240 |
Why?
|
| Treatment Outcome | 15 | 2025 | 13105 | 0.230 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 500 | 0.230 |
Why?
|
| Immunity, Cellular | 1 | 2025 | 206 | 0.220 |
Why?
|
| Presenteeism | 2 | 2023 | 2 | 0.220 |
Why?
|
| Bias | 1 | 2024 | 147 | 0.220 |
Why?
|
| Age Factors | 9 | 2025 | 2997 | 0.210 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 12 | 0.210 |
Why?
|
| Respiratory Tract Diseases | 2 | 2020 | 81 | 0.210 |
Why?
|
| Drug Utilization | 2 | 2015 | 170 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 179 | 0.200 |
Why?
|
| Acute Disease | 5 | 2018 | 1190 | 0.200 |
Why?
|
| Fluorocarbons | 1 | 2023 | 60 | 0.200 |
Why?
|
| Self Report | 4 | 2023 | 553 | 0.200 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 81 | 0.200 |
Why?
|
| Immunization Schedule | 4 | 2025 | 107 | 0.200 |
Why?
|
| RNA, Viral | 5 | 2023 | 563 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 187 | 0.190 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2001 | 37 | 0.190 |
Why?
|
| Intention | 1 | 2022 | 98 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2018 | 1333 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 810 | 0.180 |
Why?
|
| Firefighters | 1 | 2022 | 34 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 906 | 0.180 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 23 | 0.180 |
Why?
|
| Reminder Systems | 1 | 2001 | 66 | 0.180 |
Why?
|
| Carrier State | 1 | 2021 | 78 | 0.180 |
Why?
|
| Vaccination Coverage | 4 | 2023 | 37 | 0.170 |
Why?
|
| Liver Diseases | 1 | 2025 | 392 | 0.170 |
Why?
|
| Coinfection | 1 | 2022 | 183 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 757 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 5 | 0.160 |
Why?
|
| Viral Vaccines | 1 | 2023 | 345 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2022 | 183 | 0.160 |
Why?
|
| Hospitals | 4 | 2024 | 440 | 0.160 |
Why?
|
| Antigenic Variation | 1 | 2020 | 42 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 3119 | 0.160 |
Why?
|
| Mycobacterium marinum | 1 | 1999 | 1 | 0.160 |
Why?
|
| Oregon | 3 | 2014 | 10 | 0.160 |
Why?
|
| Cheek | 1 | 1999 | 25 | 0.160 |
Why?
|
| Immunity, Herd | 4 | 2024 | 13 | 0.150 |
Why?
|
| Incidence | 6 | 2025 | 3424 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1999 | 44 | 0.150 |
Why?
|
| Vaccines | 1 | 2024 | 380 | 0.150 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 243 | 0.150 |
Why?
|
| Specimen Handling | 2 | 2022 | 149 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 42 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2024 | 1722 | 0.140 |
Why?
|
| Abscess | 1 | 1999 | 140 | 0.140 |
Why?
|
| Antibody Specificity | 2 | 2013 | 203 | 0.140 |
Why?
|
| Enterococcus faecalis | 1 | 1997 | 49 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 492 | 0.130 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 79 | 0.130 |
Why?
|
| Laboratories | 3 | 2021 | 89 | 0.130 |
Why?
|
| Office Visits | 2 | 2015 | 78 | 0.130 |
Why?
|
| Washington | 2 | 2013 | 35 | 0.130 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2013 | 23 | 0.130 |
Why?
|
| Accidents, Home | 1 | 1996 | 9 | 0.130 |
Why?
|
| Texas | 6 | 2013 | 3719 | 0.130 |
Why?
|
| Foot Injuries | 1 | 1996 | 9 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 638 | 0.130 |
Why?
|
| Mediastinal Emphysema | 1 | 1996 | 11 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2024 | 890 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 1996 | 18 | 0.130 |
Why?
|
| Medication Errors | 1 | 2018 | 207 | 0.120 |
Why?
|
| Immunization | 3 | 2023 | 315 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2017 | 277 | 0.120 |
Why?
|
| Antibodies, Bacterial | 1 | 1997 | 407 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 3 | 2025 | 498 | 0.120 |
Why?
|
| Efficiency | 1 | 2015 | 70 | 0.120 |
Why?
|
| Time Factors | 5 | 2025 | 6595 | 0.120 |
Why?
|
| Neutrophils | 1 | 1997 | 401 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 4008 | 0.110 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2025 | 153 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2592 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 1996 | 214 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 1996 | 251 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 1996 | 345 | 0.100 |
Why?
|
| Risk Factors | 6 | 2025 | 11196 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 1995 | 248 | 0.100 |
Why?
|
| Logistic Models | 3 | 2025 | 1909 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 772 | 0.090 |
Why?
|
| Schools | 1 | 2014 | 237 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 759 | 0.090 |
Why?
|
| Hepatitis A Antibodies | 1 | 2011 | 9 | 0.090 |
Why?
|
| Hepatitis A Vaccines | 1 | 2011 | 10 | 0.090 |
Why?
|
| Chickenpox Vaccine | 1 | 2011 | 14 | 0.090 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2011 | 14 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2020 | 1338 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 414 | 0.090 |
Why?
|
| History, 21st Century | 3 | 2017 | 277 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2022 | 315 | 0.080 |
Why?
|
| Reference Standards | 2 | 2021 | 247 | 0.080 |
Why?
|
| Oxygen | 2 | 2023 | 580 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2440 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1388 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 607 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1630 | 0.080 |
Why?
|
| Nose | 2 | 2020 | 105 | 0.070 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 72 | 0.070 |
Why?
|
| Oropharynx | 2 | 2020 | 39 | 0.070 |
Why?
|
| Comorbidity | 2 | 2019 | 1628 | 0.060 |
Why?
|
| Parents | 2 | 2024 | 1072 | 0.060 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2025 | 34 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2022 | 1251 | 0.060 |
Why?
|
| Drainage | 2 | 1996 | 265 | 0.050 |
Why?
|
| Immunologic Memory | 1 | 2025 | 200 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 833 | 0.050 |
Why?
|
| Propensity Score | 1 | 2025 | 263 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 158 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 46 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 2022 | 25 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 247 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
|
| Dyspnea | 1 | 2024 | 160 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 202 | 0.050 |
Why?
|
| Police | 1 | 2022 | 14 | 0.050 |
Why?
|
| Perception | 1 | 2024 | 237 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 24 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 27 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 238 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 375 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 33 | 0.050 |
Why?
|
| Epitopes | 1 | 2024 | 444 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 3754 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 709 | 0.050 |
Why?
|
| Nasopharynx | 2 | 2013 | 87 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 132 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 217 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 76 | 0.040 |
Why?
|
| Documentation | 1 | 2022 | 122 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 88 | 0.040 |
Why?
|
| Absenteeism | 2 | 2014 | 19 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 247 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 325 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 227 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1512 | 0.040 |
Why?
|
| Proteomics | 1 | 2024 | 604 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 1982 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2171 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1176 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 81 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17591 | 0.040 |
Why?
|
| Pharyngitis | 1 | 2018 | 34 | 0.040 |
Why?
|
| School Health Services | 2 | 2010 | 102 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 45 | 0.040 |
Why?
|
| Blood Bactericidal Activity | 1 | 1997 | 17 | 0.040 |
Why?
|
| Opsonin Proteins | 1 | 1997 | 20 | 0.040 |
Why?
|
| Medical Records | 1 | 2018 | 194 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 479 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2019 | 186 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2021 | 430 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 1997 | 59 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2021 | 541 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2017 | 65 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1161 | 0.030 |
Why?
|
| Sinusitis | 1 | 2018 | 114 | 0.030 |
Why?
|
| Pharynx | 1 | 2017 | 69 | 0.030 |
Why?
|
| Frailty | 1 | 2019 | 134 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 551 | 0.030 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 89 | 0.030 |
Why?
|
| Phagocytosis | 1 | 1997 | 194 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2016 | 23 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1735 | 0.030 |
Why?
|
| Fusarium | 1 | 1996 | 13 | 0.030 |
Why?
|
| Tibia | 1 | 1996 | 83 | 0.030 |
Why?
|
| Prevalence | 1 | 2023 | 2685 | 0.030 |
Why?
|
| Pregnancy | 2 | 2022 | 7600 | 0.030 |
Why?
|
| Bacillus | 1 | 1996 | 38 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3759 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1996 | 91 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2023 | 804 | 0.030 |
Why?
|
| Health Services | 2 | 2006 | 73 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2015 | 6 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1997 | 320 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2265 | 0.030 |
Why?
|
| Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1626 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 723 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1996 | 195 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 826 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2017 | 8640 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 305 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2013 | 52 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 65 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 2449 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 1183 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 432 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 1312 | 0.020 |
Why?
|
| Recurrence | 1 | 1995 | 1470 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 260 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5466 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 965 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 70 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 239 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 445 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 404 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2010 | 135 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 198 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 288 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 2204 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1666 | 0.020 |
Why?
|
| Family Health | 1 | 2006 | 268 | 0.020 |
Why?
|
| Michigan | 1 | 2005 | 52 | 0.010 |
Why?
|
| Japan | 1 | 2005 | 155 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1588 | 0.010 |
Why?
|